- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.06. | Turnstone Biologics Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.06. | Turnstone, once allied with AbbVie and Takeda, accepts $8M Xoma buyout | 11 | FierceBiotech | ||
| 27.06. | XOMA-Aktie steigt nach Übernahme von Turnstone Biologics | 1 | Investing.com Deutsch | ||
| 27.06. | XOMA stock rises after acquisition of Turnstone Biologics | 1 | Investing.com | ||
| 27.06. | Turnstone Biologics to be acquired by XOMA Royalty | 3 | Seeking Alpha | ||
| TURNSTONE BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 27.06. | XOMA Royalty to acquire Turnstone Biologics for $0.34 per share | 2 | Investing.com | ||
| 27.06. | Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right | 159 | GlobeNewswire (Europe) | EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (Nasdaq: XOMA) and Turnstone Biologics Corp. ("Turnstone" or the "Company") (Nasdaq-CM:... ► Artikel lesen | |
| 09.05. | Turnstone Biologics GAAP EPS of -$0.51 | 2 | Seeking Alpha | ||
| 09.05. | Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights | 70 | GlobeNewswire (Europe) | SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (Nasdaq-CM: TSBX), a biotechnology company historically focused on the development of a differentiated... ► Artikel lesen | |
| 31.03. | Turnstone Biologics GAAP EPS of -$0.56 misses by $0.36 | 2 | Seeking Alpha | ||
| 29.03. | Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results | 411 | GlobeNewswire (Europe) | SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (Nasdaq: TSBX), a biotechnology company historically focused on the development of a differentiated... ► Artikel lesen | |
| 05.02. | Piper Sandler cuts Turnstone Biologics stock rating to neutral | 1 | Investing.com | ||
| 04.02. | Turnstone ends last remaining clinical program due to costs, plots more layoffs | 1 | FierceBiotech | ||
| 04.02. | Turnstone Biologics stoppt TIDAL-01-Entwicklung und sucht nach Alternativen | 1 | Investing.com Deutsch | ||
| 04.02. | Turnstone Biologics halts TIDAL-01 development, seeks alternatives | 4 | Investing.com | ||
| 04.02. | Turnstone Biologics Corp.: Turnstone Biologics Announces Plans to Explore Strategic Alternatives | 162 | GlobeNewswire (Europe) | SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (Nasdaq: TSBX) today announced that it has completed an assessment of its business and operations... ► Artikel lesen | |
| 04.02. | Turnstone Biologics Corp. - 8-K, Current Report | - | SEC Filings | ||
| 11.10.24 | Turnstone Biologics Corp.: Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway | 859 | GlobeNewswire (Europe) | Realigning resources to focus on clinical advancement of Selected TIL therapyReducing employee headcount by approximately 60%Streamlining operations with cash runway expected to extend into 2Q 2026... ► Artikel lesen | |
| 14.08.24 | Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights | 235 | GlobeNewswire (Europe) | Announced positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer including a complete response in one of the four patients reported Cash position expected to fund operations... ► Artikel lesen | |
| 14.08.24 | Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer | 216 | GlobeNewswire (Europe) | Overall response rate ("ORR") of 25% and 50% disease control rate ("DCR") observed in first four evaluable patients treated with TIDAL-01 with advanced CRC Complete response achieved in heavily pre-treated... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,115 | 0,00 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
| BIOXXMED | 0,410 | 0,00 % | EQS-News: bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024 | EQS-News: bioXXmed AG
/ Schlagwort(e): Jahresbericht
bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024
27.06.2025 /... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
| OCUGEN | 0,800 | -2,39 % | Ocugen erhält zusätzliche 180-Tage-Verlängerung von der Nasdaq | ||
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
| BIO-GATE | 0,920 | +0,55 % | Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | Nürnberg (www.anleihencheck.de) - Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts - AnleihenewsVorstand und Aufsichtsrat der Bio-Gate AG (ISIN DE000BGAG981/... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,464 | +2,43 % | Defence Therapeutics Inc.: Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology | Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
| VAXART | 0,381 | +3,75 % | Vaxart wird vom Nasdaq ausgesetzt und plant Berufung gegen Delisting-Entscheidung | ||
| BURCON NUTRASCIENCE | 2,190 | +7,09 % | Burcon NutraScience Corporation: Burcon to Showcase Café Latte Plant Protein Beverage at 2025 IFT FIRST Annual Event & Expo | Vancouver, British Columbia--(Newsfile Corp. - July 2, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 4,630 | -3,54 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option | ||
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| AIM IMMUNOTECH | 7,700 | 0,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies | ||
| IMMUNIC | 0,626 | +1,29 % | EQS-News: Immunic AG: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Study/Study results
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,086 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| CEL-SCI | 2,500 | +2,04 % | Pre-market Movers: Navitas Semiconductor, Longevity Health, CEL-SCI, Hyperscale Data, Sunrun | PHILADELPHIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 06.35 A.M. ET).In the Green Navitas Semiconductor Corporation (NVTS) is... ► Artikel lesen |
TURNSTONE BIOLOGICS CORP gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,06 % bei einem Aktienkurs von 0,362 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TURNSTONE BIOLOGICS CORP finden Sie auf Wallstreet Online.